Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Five latent factors underlie response to immunotherapy.
Usset J, Rosendahl Huber A, Andrianova MA, Batlle E, Carles J, Cuppen E, Elez E, Felip E, Gómez-Rey M, Lo Giacco D, Martinez-Jimenez F, Muñoz-Couselo E, Siu LL, Tabernero J, Vivancos A, Muiños F, Gonzalez-Perez A, Lopez-Bigas N. Usset J, et al. Among authors: siu ll. Nat Genet. 2024 Oct;56(10):2112-2120. doi: 10.1038/s41588-024-01899-0. Epub 2024 Sep 12. Nat Genet. 2024. PMID: 39266764 Free PMC article.
New drug development in digestive neuroendocrine tumors.
Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J, Tabernero J. Durán I, et al. Among authors: siu ll. Ann Oncol. 2007 Aug;18(8):1307-13. doi: 10.1093/annonc/mdm009. Epub 2007 Feb 13. Ann Oncol. 2007. PMID: 17301070 Free article. Review.
SARS-CoV-2 vaccination and phase 1 cancer clinical trials.
Yap TA, Siu LL, Calvo E, Lolkema MP, LoRusso PM, Soria JC, Plummer R, de Bono JS, Tabernero J, Banerji U. Yap TA, et al. Among authors: siu ll. Lancet Oncol. 2021 Mar;22(3):298-301. doi: 10.1016/S1470-2045(21)00017-6. Epub 2021 Feb 8. Lancet Oncol. 2021. PMID: 33571468 Free PMC article. No abstract available.
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
Van Cutsem E, Yaeger R, Delord JP, Tabernero J, Siu LL, Ducreux M, Siena S, Elez E, Kasper S, Zander T, Steeghs N, Murphy D, Edwards M, Wainberg ZA. Van Cutsem E, et al. Among authors: siu ll. Oncologist. 2023 Dec 11;28(12):e1209-e1218. doi: 10.1093/oncolo/oyad210. Oncologist. 2023. PMID: 37597246 Free PMC article. Clinical Trial.
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer.
Hernando-Calvo A, Han M, Ayodele O, Wang BX, Bruce JP, Abbas-Aghababazadeh F, Vila-Casadesús M, Sanz-Garcia E, Yang SYC, Berman HK, Vivancos A, Lam B, Lungu I, Salawu A, Stayner LA, Haibe-Kains B, Bedard PL, Avery L, Razak ARA, Pugh TJ, Spreafico A, Siu LL, Hansen AR. Hernando-Calvo A, et al. Among authors: siu ll. Clin Colorectal Cancer. 2024 Sep;23(3):272-284.e9. doi: 10.1016/j.clcc.2024.05.002. Epub 2024 May 15. Clin Colorectal Cancer. 2024. PMID: 38960798 Free article. Clinical Trial.
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.
Hernando-Calvo A, Yang SYC, Vila-Casadesús M, Han M, Liu ZA, Berman AHK, Spreafico A, Razak AA, Lheureux S, Hansen AR, Lo Giacco D, Abbas-Aghababazadeh F, Matito J, Haibe-Kains B, Pugh TJ, Bratman SV, Aleshin A, Berche R, Saavedra O, Garralda E, Elston S, Siu LL, Ohashi PS, Vivancos A, Bedard PL. Hernando-Calvo A, et al. Among authors: siu ll. JCO Precis Oncol. 2024 Aug;8:e2400100. doi: 10.1200/PO.24.00100. JCO Precis Oncol. 2024. PMID: 39178369 Free PMC article. Clinical Trial.
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, Anak Ö, Hackl W, Baselga J. Markman B, et al. Ann Oncol. 2012 Sep;23(9):2399-2408. doi: 10.1093/annonc/mds011. Epub 2012 Feb 22. Ann Oncol. 2012. PMID: 22357447 Free article. Clinical Trial.
Tumour heterogeneity in the clinic.
Bedard PL, Hansen AR, Ratain MJ, Siu LL. Bedard PL, et al. Among authors: siu ll. Nature. 2013 Sep 19;501(7467):355-64. doi: 10.1038/nature12627. Nature. 2013. PMID: 24048068 Free PMC article.
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J. Wainberg ZA, et al. Among authors: siu ll. Target Oncol. 2017 Dec;12(6):775-785. doi: 10.1007/s11523-017-0530-5. Target Oncol. 2017. PMID: 29067643 Free PMC article. Clinical Trial.
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ. Cindy Yang SY, et al. Among authors: siu ll. Nat Commun. 2021 Aug 26;12(1):5137. doi: 10.1038/s41467-021-25432-7. Nat Commun. 2021. PMID: 34446728 Free PMC article. Clinical Trial.
434 results